Podcast

Advancing Precision Oncology With the Syapse Precision Medicine Council

In June, Syapse—a company that works with health systems to implement precision medicine across its organizations—took the next step in leading the shift toward precision medicine by launching the Syapse Precision Medicine Council.

In June, Syapse—a company that works with health systems to implement precision medicine across its organizations—took the next step in leading the shift toward precision medicine by launching the Syapse Precision Medicine Council. The council consists of oncology, operations, and research leaders from health systems dedicated to advancing precision medicine through sharing strategies and insights in order to identify best practices.

Dennis Shin, chief commercial officer of Syapse, discussed the formation of the council, how it plans to disrupt the current precision oncology landscape, and what he sees for the future of the council.

To listen, login to the website.

Listen above or through one of these podcast services:

iTunes: http://apple.co/2eYWTss?rel=0"

TuneIn: http://bit.ly/2gv7iwj?rel=0"

Stitcher: http://bit.ly/2gCqtFg?rel=0"

Syapse, Roche Team Up to Advance Precision Medicine in Oncology

Syapse Looks to Expand Precision Medicine Partnerships With New CEO

Oncologists Are Crucial to Advancing Precision Medicine

Precision Health AI Launches Platform to Deliver Data-Driven Insights in Oncology

Using Health IT to Increase Medication Adherence and Enhance Precision Medicine

Read more about Syapse and precision oncology:

Related Videos
Nini Wu, MD, Navista
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Pieter Sonneveld, MD, PhD
Lalan Wilfong, MD
Katherine Baker, MD, MMHC
Nini Wu, MD, MBA
Andrew Chapman, DO
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Related Content
In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com
May 22nd 2025

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

Rose McNulty
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Managed Care Cast
May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville
Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com
May 18th 2025

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

Jared Kaltwasser
The tool could make it easier for clinicians to rule out melanoma without the need for excision.
managed care cast logo
May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS
Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
FDA Approved | Image credit: chrisdorney – stock.adobe.com
May 14th 2025

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

Hayden E. Klein
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com
May 14th 2025

Flow Cytometry Can Reliably Identify CTC in Melanoma

AJMC Contributor
The study, which used flow cytometry rather than molecular biology to identify circulating tumor cells (CTCs), found a significant positive correlation between the number of CTCs and the stage of disease.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo